• Eisai and Biogen recently announced that the FDA has extended by three months its review of the supplemental Biologics License Application for LEQEMBI IQLIK, a once-weekly subcutaneous starting dose for early Alzheimer’s disease, moving the PDUFA action date to August 24, 2026, after requesting additional information classified as a major amendment.
• While the FDA extension slows the U.S. timeline, the absence of raised approvability concerns and LEQEMBI’s broad global approvals keep attention on how this new formulation could fit into real-world Alzheimer’s treatment patterns.
• We’ll now examine how the FDA’s extended review of once-weekly LEQEMBI IQLIK may influence Biogen’s investment narrative and risk profile.

AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Biogen Investment Narrative Recap

To own Biogen, you have to believe that a focused neurology portfolio can offset pressure on older MS drugs through successful launches like LEQEMBI, SKYCLARYS, and ZURZUVAE. The FDA’s three‑month extension for LEQEMBI IQLIK slightly delays a near term Alzheimer’s catalyst but does not materially alter the core risk that Biogen’s future still hinges on a small number of new therapies performing to expectations.

The recent Q1 2026 earnings report is particularly relevant here, as it shows Biogen generating US$2,477.8 million in revenue and US$319.5 million in net income even as one off items and MS competition weigh on results. That financial footing gives Biogen some flexibility to absorb regulatory timing shifts like the LEQEMBI IQLIK delay while it waits to see how key neurologic assets contribute to earnings.

However, beneath this relatively modest delay, investors should be aware of the concentration risk around Biogen’s next wave of neurology launches, including...

Biogen's narrative projects $9.4 billion revenue and $2.1 billion earnings by 2028.

Uncover how Biogen's forecasts yield a $205.67 fair value, a 6% upside to its current price.

Exploring Other Perspectives

Some analysts were far more optimistic before this news, assuming Biogen could reach about US$11.8 billion in revenue and US$2.5 billion in earnings by 2029, so you should compare that upbeat view on faster LEQEMBI adoption with the risk that heavy reliance on a narrow neurology portfolio leaves results very exposed if regulatory timelines, reimbursement, or competition evolve differently than these forecasts expect.

Explore 7 other fair value estimates on Biogen - why the stock might be worth over 2x more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Biogen research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Biogen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Biogen's overall financial health at a glance.

Want Some Alternatives?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 33 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.